International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction | Post ADDIKD Implementation Survey

Survey link: https://www.surveymonkey.com/r/5QHCMZD

The survey will be open till Sunday 13th October 2024

What do I need to do?

You are invited to complete this survey if you are a healthcare professional (medical oncologist, haematologist, pharmacist, nurse or allied health) who cares for people with cancer at Australian or New Zealand hospitals.

The survey is anonymous (unless you enter the competition) and will take approximately 15 minutes to complete.

Who is conducting the survey?

eviQ and the Cancer Institute NSW developed and published The International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) in October 2022. Starting in July 2023, eviQ proceeded to implement the ADDIKD guideline recommendations into 700+ eviQ drug treatment protocols. This was completed in June 2024.

Why are we undertaking this survey?

The following survey questions are intended to gain an understanding of the impact of the ADDIKD guideline and the implementation of its recommendations into eviQ drug treatment protocols on clinician practice and cancer centres.

Prize draw

By completing the survey you can go into the draw to win one of four $50 gift vouchers (for respondents in Australia).

For further information on the ADDIKD guideline and implementation of the recommendations into eviQ protocols please visit the eviQ ADDIKD webpage or contact Liesel Byrne.